Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good plan unless it gaps higher and then the chase is on. Profit is always good. From .035 to .07 is a major move in 3 days. Nothing goes straight up.
Everyone always sell at the HOD.. will be ready to buy at LOD.. unless it gaps higher at the open. GLTA
Nothing wrong with taking profits.. why we do this.. can't complain about 37% uptick.
the patent application was submitted in 2016.. the patent was approved and sent to the final document review last week.
Other Bios are already looking into MIPSAGARGIN
MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
PDF Version
LA JOLLA, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent has improved therapeutic claims compared to the first patent which covers MN-166 (ibudilast) for the treatment of glioblastoma, which was granted last year, and has a later expiration date than the first patent.
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, wherein the patient expresses methylated MGMT (O6-methylguanine-DNA methyltransferase), using MN-166 (ibudilast) in combination with one or more other therapeutic agents including temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cover a wide range of doses of MN-166 (ibudilast) during an optionally repeating dosing cycle. The allowed claims also cover different types of glioblastoma including classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma.
The old Lewis and Clark website (lncpharma.com) is still around if you want to see what NSPX received in the merger with L&C.
Totally miniscule market cap for what this ticker has to offer investors in cancer therapy. Now with Ridgeway and Colin Hislop on board and in control with the work they have done on immuno-oncology the value of the ticker should increase by many multiples. The deal with Ridgeway is the game changer that was expected.
Just the fact that Inspyr took the step and released control to a bonified biotech professional (Colin Hislop) should give optimism to the ticker. Since 2016 when Chris Lowe (my vote for worst CEO of century) (financial genius in his own mind) took control and ran the company into the ground and then Michael Cain (pure figure head) the company had no clue on what was going on.. really lost. With Colin in control things should change to the better ..it is impossible for him to do worse than the previous management that was in control.
NO.. the patent was applied for in 2016! The patent has been approved.. on friday 10/9 the patent paperwork was sent for FDC (final document collection) for review prior to physically printing the patent, issuing a patent number and then sending out the package to applicant .. in this case Phyton Biotech.
I've seen these runs before in this ticker that's why I loaded up after last RS when it broke below .01. easy money! always have believed that something will come out of all the IP. These runs have a tendency to run their course so play it smart.. money to be had.
Phyton will have the USPTO patent to produce the thapsigargin within weeks. It has already been approved and is in FDC (final document capture) stage. This has been long in coming it was applied for in 2016. Phyton is world leader in PCF (plant cell fermentation) technology and also is the world leader in the production of TAXOL another plant based cancer drug.
Transaction History
Date Transaction Description
10-09-2020 Dispatch to FDC
09-29-2020 Application Is Considered Ready for Issue
09-25-2020 Issue Fee Payment Verified
09-28-2020 Printer Rush- No mailing
09-28-2020 Printer Rush- No mailing
09-25-2020 Issue Fee Payment Received
09-19-2020 Pubs Case Remand to TC
08-14-2020 Electronic Review
08-14-2020 Email Notification
08-14-2020 Mail Notice of Allowance
08-07-2020 Notice of Allowance Data Verification Completed
One of the best part of the Ridgeway deal is that Colin Hislop will take control of Inspyr. No more figureheads who know nothing of moving drugs thru to the market!
Colin Hislop, MD
SENIOR VICE PRESIDENT, CLINICAL AND DEVELOPMENT OPERATIONS
-
Colin Hislop has over 30 years of experience in drug development including small molecules, peptides and biologics, across therapeutic areas in both large pharma and start-up companies. Prior to joining Eiger full-time, Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies.
Prior to joining Eiger, Dr. Hislop served as Chief Medical Officer at Versartis and Anthera. He was previously Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem for systemic infections. Peninsula was acquired by J&J for $245 million. Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa for angina. CV Therapeutics was acquired by Gilead for $1.4 billion. He previously led the development of Actonel through initial FDA approvals for osteoporosis at Proctor & Gamble. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4, and has led numerous US, European, and global regulatory filings, including 4 NDAs.
Dr. Hislop earned a Bachelor of Science in Medical Biochemistry from the University of Surrey and a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) at the University of London.
Colin Hislop is the real deal!
Ridgeway ceo Colin Hislop is well know in the biotech world not only in USA but also in Europe ( he’s from England). Ridgeway is a private co and no telling who is backing up the company financially and what their plans are for NSPX since they now have control!
Another event on the horizon is Phyton Biotech is within weeks of finally obtaining the patent on the commercial production of Thapisgargin (active ingredient in mipsagargin). The patent application has been approved and is in the final document capture (FDC) stage. Now that that the supply chain problem of thapsigargin is solved this may well be the event that kick starts mipsagargin into a PH III trial.
Bio is uncertain..who knows (no one on this site) this novel platform developed from adenosine by Ridgeway may be worth 50 million!
8-K filed 10/8
This novel immuno-oncology delivery technology (RT-AR001) must be the real deal to give up almost half of your common shares (65 million of 150 million) and who knows what is the fine print in the 8000 preferred shares!
Just a guess but it looks like after NSPX merged with L&C they received the adenosine antagonist receptor technology. They then partnered with Ridgeway to enhance this antagonist into a immuno-oncology delivery technology. The partnership with Ridgeway included payments of up to 12 million plus other payments (see press release dated 9/17/2018). Never happened..no mention in any of the filings that any money ever was transmitted to NSPX. NSPX is buying the enhanced adenosine technology back from Ridgeway for common and preferred stock. The big question is why. Maybe NSPX has a new and better deal that is actually going to pay some cash!
NSPX may have a buyer or partner in line for the RT-AR 001 intra-tumor delivery technology and Ridgeway hasn't lived up to the agreements in their partnership. Colin Hislop working full time at Eiger probably couldn't dedicate the time necessary to move the technology along fast enough. Anyway, we'll see what happens any news from NSPX may be good news.
Barring further roadblocks from the USPTO Phyton Biotech will be soon issued the long awaited patent for the production of thapsigargin (active ingredient in Inspyrs drug Mipsagargin). Phyton plans to use Plant Cell Fermentation (PCF) technology to mass produce the drug. This PCF technology is the same technology used to produce TAXOL (made from the bark of pacific Yew tree). TAXOL is a leading chemotherapy drug and Phyton is the worlds major producer of the drug.
This may eliminate one of the risk factors designated in recent 10-Q.
Our therapeutic compounds may not be able to be manufactured profitably on a large enough scale to support commercialization.
To date, prior to our curtailment of operations, our therapeutic compounds have only been manufactured at a scale which is adequate to supply our research activities and early-stage clinical trials. There can be no assurance that the procedures currently used to manufacture our therapeutic compounds will work at a scale which is adequate for commercial needs. In the event our therapeutic compounds cannot be manufactured in sufficient quantities for commercialization, our future prospects could be significantly impacted and our financial prospects would be materially harmed.
The ink wasn't dried on that optimistic and forward looking press release (September 2017) that Chris Lowe 5 short months later shut down the company (February 2018). Strategic planning at its worst. Showed his hand that fishing for patents was his true purpose as CEO (no chance for him to run a bio company). So far both Inspyr patents and L&C patents have not generated any interest and/or value. The RS is just a method to stay in the game until/if something materializes.
Came from a press release concerning the merger of Inspyr and Lewis and Clark Septemer 13, 2017
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
No one listening...multi million share buys every day! Torching investors has been business as usual for NSPX!
In Feb, 2015 Genspera (now Inspyr) entered into the strategic partnership with Phyton Biotech for the manufacture of thapsigargin. At the time it seemed like a major milestone in the development of mipsagargin. No one could foresee that it would take four long years for the patent to manufacture thapsigargin to go thru the rigors of the USPTO. Whether the original partnership is still in place is any ones guess. With no viable supply of thapsigargin, mipsagargin is on the shelve collecting dust. What started as a optimistic therapy for killer cancers developed by renowned scientists at John Hopkins University Clinic is now thru totally inept management a shell of what it should be. Disappointing for sure!
FYI or for what its worth.. USPTO (united states patent and trade office) received the $500.00 patent issue fee from Phyton Biotech on 9/25/2020. This patent is for Production of Thapsigargin by Thapsia Cell Suspension Culture. Thapsigargin is the active ingredient in mipsagargin. The original patent application was filed on 6/01/16. The patent should be formally issued soon. Whether this development has any effect on NSPX remains to be seen.
Puzzling that how poorly NSPX has performed over time there are still buyers of multi million shares per day. The dilution will continue until ( or if)the market dries up which right now doesn't seem it's going to happen.
How true.. there are many at this time that wish they have never heard of Genspera/Inspyr or Mipsagargin/thapisgargin or followed anything to do with NSPX. Disappointing for sure! Presently all that was anticipated with this ticker has not happened.
Whoa..not so fast my friend! We know who is diluting..we know who is converting.. but we don't know who is buying or why the the volume continues at a brisk pace. Not over yet and I wouldn't agree on anything.
What has transpired with NSPX since FLG Partners and Chris Lowe (infamous financial expert) ran this stock directly into the ground is criminal! The recent actions over the last few years can not leave anyone confident that NSPX has a heartbeat and will recover from the malaise that it is in. However, it is a bio tech stock with some IP and no one should be so naive that they can foretell the future especially in these crazy times.
Seems there are always buyers for low risk high reward bios that may have a chance to advance especially ones with patents and orphan designation protecting IP. No matter how poor the performance has been there is always a future and no one knows what is out there.
Who or better yet WHY is anyone buying this stock?
400,000 shares in last 2 minutes???
NSPX hanging in there as they survive until something breaks with the IP. When the chase begins it will happen fast and furious like it did a few months back so be there or be square!
Since NSPX shut down operations in Feb 18 they have filed 27 SEC reports detailing the happenings of the company and are now current. I agree they have filed no "BOGUS" press releases to pump the company. It may appear that they are doing what many pre-revenue clinical bio companies do that is survive until something happens with their IP.
Ha! There is always hope I guess. Other posters have been correct in that this pattern repeats itself. A RS and NSPX does nothing to (or doesn't want to) or can't defend the PPS and there is a low volume slide back to pre RS prices. Frustrating for sure. It has happened before and may happen again. For years Genspera/Inspyr proponents blamed the lack of development of mipsagargin for the lack of a supply chain for thapsigargin. The hope is now with the pending patent for Phyton some one will pick up mipsagargin and take it into PH III.
Our therapeutic compounds may not be able to be manufactured profitably on a large enough scale to support commercialization.
To date, prior to our curtailment of operations, our therapeutic compounds have only been manufactured at a scale which is adequate to supply our research activities and early-stage clinical trials. There can be no assurance that the procedures currently used to manufacture our therapeutic compounds will work at a scale which is adequate for commercial needs. In the event our therapeutic compounds cannot be manufactured in sufficient quantities for commercialization, our future prospects could be significantly impacted and our financial prospects would be materially harmed.
This has been a recurring RISK FACTOR in all of the NSPX filings. It also, some believe, may have been a reason why NSPX has not progressed into a PH III trial and /or why further development of the drug has been halted. Now with the pending issuance of the PHYTON production patent for thagsigargin this may all change and interest in MIPSAGARGIN may increase.
On 4/20/2020 A MediciNova press release noted that they received a NOA (notice of allowance) from the USPTO for a patent covering their drug MN-166 (ibudilast) for the treatment of brain cancer. The patent included a possible combination therapy with MN-166 and other drugs including MIPSAGARGIN. You would think since NSPX owns MIPSAGARGIN there would be some sort of agreement between NSPX and MediciNova for the basis of a collaboration. Yet no mention of this in the 2nd quarter 10-Q.. Why?
I would look to Raul Silvestre ..lawyers bill clients for all services rendered. His office is listed as NSPX corporate office so anything generated from there would be billed accordingly. He may be also providing corporate administration services thru Cain and would bill that with his entitled markup. Silvestre is an experienced corporate lawyer and probably has honed his craft on how to maintain cash flow.
Good to see that they filed on time and that there was no default on the debentures (maturity date extended until December 31, 2020. Other than that nothing to get excited about (boilerplate) and nothing to change the course of this ticker..low volume slide?
SAN ANTONIO, Feb. 9, 2015 — GenSpera, Inc. (OTCQB: GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company’s investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high-quality thapsigargin.
“This partnership will revolutionize the way we obtain thapsigargin to develop our drugs, enabling us to boost supply and reduce the impurities that can arise when it is extracted from naturally grown plants,” said Craig Dionne, Ph.D., chief executive officer at GenSpera. “By working with Phyton Biotech, we are leveraging state-of-the-art biotech that has the potential to improve the efficiency of our production process. It is through these kinds of partnerships that we can not only develop new drug candidates, but do so in a way that creates increased product value.”
This patent has been a long time coming. Whether it benefits NSPX remains to be see but is something that has been in the works and finally a patent to produce the drug in a robust quantity and reasonable cost!